SEC Form 4 · accession 0001536639-26-000004
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seamus Mulligan
Director
Period of report
Aug 5, 2026
Accepted (ET)
Aug 7, 2026 · 5:42 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Aug 5, 2026 | A | 1,605 | $0.00 | A | 1,184,633 | D | |
| Ordinary SharesF2 | holding | — | — | — | 101,621 | I | By Nerano Pharma Lim |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027.
- F2Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family.